Artiva Biotherapeutics Reports Initial AB-101 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ARTV?
Source: Newsfilter
- Promising Clinical Data: In the company-sponsored Phase 2a trial, AB-101 demonstrated a 71% ACR50 response rate in refractory rheumatoid arthritis patients, with no relapses or need for new immunomodulatory agents, indicating its potential and safety in treatment.
- FDA Trial Design Alignment: The U.S. FDA has aligned on a Phase 3 registrational randomized controlled trial evaluating AB-101 in combination with rituximab, set to initiate in H2 2026 with approximately 150 refractory RA patients, targeting ACR50 response as the primary endpoint.
- Multiple Academic Presentations: Artiva plans to present several oral and poster presentations at EULAR 2026, including late-breaking data on AB-101's clinical efficacy in refractory RA, Sjögren's disease, and systemic sclerosis, further validating its mechanism and clinical activity.
- Strong Financial Position: As of March 31, 2026, Artiva reported $86.8 million in cash and investments, expected to fund operations into Q2 2027, with R&D expenses of $19.3 million, reflecting the company's ongoing commitment to clinical development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARTV
Wall Street analysts forecast ARTV stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.520
Low
15.00
Averages
18.67
High
23.00
Current: 12.520
Low
15.00
Averages
18.67
High
23.00
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artiva Biotherapeutics Q1 Financial Report Analysis
- Financial Performance: Artiva Biotherapeutics reported a Q1 GAAP EPS of -$0.95 for 2026, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, Artiva had cash, cash equivalents, and investments totaling $86.8 million, which is expected to fund operations into Q2 2027, reflecting relative stability in its cash flow situation.
- R&D Expenses: The company incurred $19.3 million in R&D expenses for Q1 2026, up from $17.1 million in Q1 2025, demonstrating a continued commitment to drug development despite financial pressures.
- Net Loss: Artiva's net loss for Q1 2026 totaled $23.5 million, widening from a loss of $20.3 million in Q1 2025, highlighting challenges in cost control and revenue generation that could impact future financing capabilities.
See More
Artiva Reports Positive Clinical Data for AlloNK Therapy
- Clinical Trial Progress: Artiva's early clinical data for the AlloNK cell therapy in difficult-to-treat rheumatoid arthritis patients shows that 71% achieved an ACR50 response after at least six months of follow-up, indicating significant symptom improvement, with no relapses or additional treatments required, highlighting the therapy's potential efficacy and safety.
- FDA Registration Trial Alignment: The U.S. FDA has aligned with Artiva on a single Phase 3 registrational trial comparing AlloNK plus Rituximab against Rituximab alone, set to begin in the second half of 2026, marking a strategic advancement in the company's autoimmune disease treatment efforts.
- Poor Financial Performance: Artiva reported a net loss of $23.5 million for Q1, with a loss of $0.95 per share, exceeding analysts' expectations of $0.86, and despite positive clinical results, this loss and a $300 million public offering negatively impacted market sentiment.
- Public Offering Details: Artiva announced the pricing of an underwritten public offering at $11.52 per share for nearly 23.9 million shares, expected to raise about $300 million in gross proceeds, although this price reflects a 9% discount from Thursday's closing price, with all securities sold directly by the company to support the development of its autoimmune disease therapies.
See More
Artiva Biotherapeutics Releases Initial Data from Mid-Stage Trial
- Clinical Trial Results: Artiva Biotherapeutics reported that in its mid-stage trial for rheumatoid arthritis, 21 patients achieved a 71% ACR50 response rate, indicating at least a 50% improvement in symptoms, showcasing the potential of its lead asset AlloNK in treatment.
- FDA Alignment Achieved: The company has reached alignment with the FDA for a single registrational trial testing AlloNK in combination with rituximab as a late-line treatment for refractory RA, expected to start in H2 2026 with nearly 150 patients and primary efficacy data readout planned for the same period.
- Funding Announcement: Artiva announced an underwritten equity offering expected to raise approximately $300 million, priced at $11.52 per share, with the offering anticipated to close around May 11, providing crucial funding for ongoing research and development.
- Financial Performance Update: Alongside the clinical data release, Artiva disclosed its Q1 2026 financials, reporting a GAAP EPS of -$0.95, reflecting the company's ongoing investments in R&D amid financial challenges.
See More
Artiva Biotherapeutics Completes Stock Offering
- Funding Size: Artiva Biotherapeutics announced an underwritten offering of 23.87 million shares priced at $11.52 each and pre-funded warrants for 2.17 million shares at $11.5199 per warrant, expected to raise approximately $300 million, significantly enhancing the company's financial strength to support clinical development.
- Market Reaction: In pre-market trading on Nasdaq, Artiva's stock surged 17.41% to $14.65, reflecting a positive market response to the offering and investor confidence in the company's future prospects.
- Transaction Timing: The offering is expected to close on or about May 11, marking a further expansion of the company's presence in the capital markets, providing necessary funding for upcoming clinical trials and product development.
- Strategic Implications: This financing allows Artiva Biotherapeutics to accelerate its clinical projects, potentially enhancing its competitive position in the biotechnology sector and attracting more investor interest in its future growth potential.
See More
Artiva Biotherapeutics Reports Initial AB-101 Clinical Data
- Promising Clinical Data: In the company-sponsored Phase 2a trial, AB-101 demonstrated a 71% ACR50 response rate in refractory rheumatoid arthritis patients, with no relapses or need for new immunomodulatory agents, indicating its potential and safety in treatment.
- FDA Trial Design Alignment: The U.S. FDA has aligned on a Phase 3 registrational randomized controlled trial evaluating AB-101 in combination with rituximab, set to initiate in H2 2026 with approximately 150 refractory RA patients, targeting ACR50 response as the primary endpoint.
- Multiple Academic Presentations: Artiva plans to present several oral and poster presentations at EULAR 2026, including late-breaking data on AB-101's clinical efficacy in refractory RA, Sjögren's disease, and systemic sclerosis, further validating its mechanism and clinical activity.
- Strong Financial Position: As of March 31, 2026, Artiva reported $86.8 million in cash and investments, expected to fund operations into Q2 2027, with R&D expenses of $19.3 million, reflecting the company's ongoing commitment to clinical development.
See More
Artiva Biotherapeutics Reports Positive Initial Clinical Data for AlloNK
- Clinical Trial Results: In the company-sponsored Phase 2a trial, 71% of refractory rheumatoid arthritis (RA) patients achieved an ACR50 response at six months, demonstrating the efficacy of AlloNK treatment and potentially laying the groundwork for future registrational trials.
- FDA Support for Registrational Trial: Artiva has aligned with the FDA to conduct a single registrational randomized controlled trial in approximately 150 refractory RA patients, primarily evaluating the efficacy of AlloNK combined with rituximab, expected to initiate in the second half of 2026.
- Good Tolerability Profile: The AlloNK treatment regimen has shown good tolerability in community rheumatology settings, with no cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported, supporting its outpatient management.
- Extensive Clinical Foundation: As of April 30, 2026, over 70 autoimmune patients have been treated with AlloNK across more than 40 clinical sites, establishing a robust clinical network that supports the upcoming registrational trial.
See More
Artiva Biotherapeutics Q1 Financial Report Analysis
- Financial Performance: Artiva Biotherapeutics reported a Q1 GAAP EPS of -$0.95 for 2026, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, Artiva had cash, cash equivalents, and investments totaling $86.8 million, which is expected to fund operations into Q2 2027, reflecting relative stability in its cash flow situation.
- R&D Expenses: The company incurred $19.3 million in R&D expenses for Q1 2026, up from $17.1 million in Q1 2025, demonstrating a continued commitment to drug development despite financial pressures.
- Net Loss: Artiva's net loss for Q1 2026 totaled $23.5 million, widening from a loss of $20.3 million in Q1 2025, highlighting challenges in cost control and revenue generation that could impact future financing capabilities.
See More
Artiva Reports Positive Clinical Data for AlloNK Therapy
- Clinical Trial Progress: Artiva's early clinical data for the AlloNK cell therapy in difficult-to-treat rheumatoid arthritis patients shows that 71% achieved an ACR50 response after at least six months of follow-up, indicating significant symptom improvement, with no relapses or additional treatments required, highlighting the therapy's potential efficacy and safety.
- FDA Registration Trial Alignment: The U.S. FDA has aligned with Artiva on a single Phase 3 registrational trial comparing AlloNK plus Rituximab against Rituximab alone, set to begin in the second half of 2026, marking a strategic advancement in the company's autoimmune disease treatment efforts.
- Poor Financial Performance: Artiva reported a net loss of $23.5 million for Q1, with a loss of $0.95 per share, exceeding analysts' expectations of $0.86, and despite positive clinical results, this loss and a $300 million public offering negatively impacted market sentiment.
- Public Offering Details: Artiva announced the pricing of an underwritten public offering at $11.52 per share for nearly 23.9 million shares, expected to raise about $300 million in gross proceeds, although this price reflects a 9% discount from Thursday's closing price, with all securities sold directly by the company to support the development of its autoimmune disease therapies.
See More
Artiva Biotherapeutics Releases Initial Data from Mid-Stage Trial
- Clinical Trial Results: Artiva Biotherapeutics reported that in its mid-stage trial for rheumatoid arthritis, 21 patients achieved a 71% ACR50 response rate, indicating at least a 50% improvement in symptoms, showcasing the potential of its lead asset AlloNK in treatment.
- FDA Alignment Achieved: The company has reached alignment with the FDA for a single registrational trial testing AlloNK in combination with rituximab as a late-line treatment for refractory RA, expected to start in H2 2026 with nearly 150 patients and primary efficacy data readout planned for the same period.
- Funding Announcement: Artiva announced an underwritten equity offering expected to raise approximately $300 million, priced at $11.52 per share, with the offering anticipated to close around May 11, providing crucial funding for ongoing research and development.
- Financial Performance Update: Alongside the clinical data release, Artiva disclosed its Q1 2026 financials, reporting a GAAP EPS of -$0.95, reflecting the company's ongoing investments in R&D amid financial challenges.
See More
Artiva Biotherapeutics Completes Stock Offering
- Funding Size: Artiva Biotherapeutics announced an underwritten offering of 23.87 million shares priced at $11.52 each and pre-funded warrants for 2.17 million shares at $11.5199 per warrant, expected to raise approximately $300 million, significantly enhancing the company's financial strength to support clinical development.
- Market Reaction: In pre-market trading on Nasdaq, Artiva's stock surged 17.41% to $14.65, reflecting a positive market response to the offering and investor confidence in the company's future prospects.
- Transaction Timing: The offering is expected to close on or about May 11, marking a further expansion of the company's presence in the capital markets, providing necessary funding for upcoming clinical trials and product development.
- Strategic Implications: This financing allows Artiva Biotherapeutics to accelerate its clinical projects, potentially enhancing its competitive position in the biotechnology sector and attracting more investor interest in its future growth potential.
See More
Artiva Biotherapeutics Reports Initial AB-101 Clinical Data
- Promising Clinical Data: In the company-sponsored Phase 2a trial, AB-101 demonstrated a 71% ACR50 response rate in refractory rheumatoid arthritis patients, with no relapses or need for new immunomodulatory agents, indicating its potential and safety in treatment.
- FDA Trial Design Alignment: The U.S. FDA has aligned on a Phase 3 registrational randomized controlled trial evaluating AB-101 in combination with rituximab, set to initiate in H2 2026 with approximately 150 refractory RA patients, targeting ACR50 response as the primary endpoint.
- Multiple Academic Presentations: Artiva plans to present several oral and poster presentations at EULAR 2026, including late-breaking data on AB-101's clinical efficacy in refractory RA, Sjögren's disease, and systemic sclerosis, further validating its mechanism and clinical activity.
- Strong Financial Position: As of March 31, 2026, Artiva reported $86.8 million in cash and investments, expected to fund operations into Q2 2027, with R&D expenses of $19.3 million, reflecting the company's ongoing commitment to clinical development.
See More
Artiva Biotherapeutics Reports Positive Initial Clinical Data for AlloNK
- Clinical Trial Results: In the company-sponsored Phase 2a trial, 71% of refractory rheumatoid arthritis (RA) patients achieved an ACR50 response at six months, demonstrating the efficacy of AlloNK treatment and potentially laying the groundwork for future registrational trials.
- FDA Support for Registrational Trial: Artiva has aligned with the FDA to conduct a single registrational randomized controlled trial in approximately 150 refractory RA patients, primarily evaluating the efficacy of AlloNK combined with rituximab, expected to initiate in the second half of 2026.
- Good Tolerability Profile: The AlloNK treatment regimen has shown good tolerability in community rheumatology settings, with no cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported, supporting its outpatient management.
- Extensive Clinical Foundation: As of April 30, 2026, over 70 autoimmune patients have been treated with AlloNK across more than 40 clinical sites, establishing a robust clinical network that supports the upcoming registrational trial.
See More
